Orbimed Advisors LLC Invests $877,000 in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Orbimed Advisors LLC purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 26,700 shares of the biopharmaceutical company's stock, valued at approximately $877,000.

Other large investors have also recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $49,290,000. Hudson Bay Capital Management LP increased its holdings in Agios Pharmaceuticals by 83.3% in the fourth quarter. Hudson Bay Capital Management LP now owns 110,000 shares of the biopharmaceutical company's stock valued at $3,615,000 after buying an additional 50,000 shares during the last quarter. Deutsche Bank AG raised its stake in Agios Pharmaceuticals by 39.7% during the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after buying an additional 265,637 shares in the last quarter. Crestline Management LP bought a new position in Agios Pharmaceuticals during the 4th quarter worth approximately $595,000. Finally, Cutter Capital Management LP lifted its holdings in Agios Pharmaceuticals by 61.6% during the 4th quarter. Cutter Capital Management LP now owns 301,623 shares of the biopharmaceutical company's stock worth $9,911,000 after buying an additional 115,000 shares during the last quarter.

Agios Pharmaceuticals Trading Up 6.7%

Shares of NASDAQ AGIO opened at $29.14 on Tuesday. Agios Pharmaceuticals, Inc. has a 12-month low of $23.42 and a 12-month high of $62.58. The company has a market cap of $1.69 billion, a PE ratio of 2.57 and a beta of 0.77. The stock has a 50 day simple moving average of $29.14 and a 200-day simple moving average of $37.06.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The company had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now owns 149,220 shares of the company's stock, valued at approximately $3,864,798. The trade was a 4.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

AGIO has been the subject of a number of research reports. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Finally, Scotiabank cut their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $56.00.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.